COMPANY PROFILE

Avalo Therapeutics

Clinical-stage biotechnology company developing IL-1beta-targeted therapies for immune-mediated inflammatory diseases

Rockville, United StatesFounded 2011Biotech & Life Sciences

Valuation $421M Market cap · 2026

Revenue $59K Latest reported FY

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting the IL-1beta (interleukin-1 beta) pathway for immune-mediated inflammatory diseases.The company's lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody designed to inhibit IL-1betaand block downstream inflammatory signaling; it is being advanced toward a registrational Phase 3 program following positive Phase 2 results in moderate-to-severe hidradenitis suppurativa,a chronic inflammatory skin condition. Avalo is also developing AVTX-010,a long-acting next-generation anti-IL-1beta monoclonal antibody intended to extend dosing intervals.

Read full description

The company is based in the United Statesand listed on the Nasdaq under the ticker AVTX.Formed from Cerecor,which changed its name to Avalo Therapeutics in 2021 following its mergerwith Aevi Genomic Medicine,the company shifted away from its earlier neuroscience focus toward immunologyand inflammation.Avalo's business model centers on research and development of novel biologic drug candidates,with eventual commercialization expected through pharmaceutical partnershipsand product sales.

Source: Dealroom company data

At a glance

Status: Listed
Founded: 2011
Headquarters: Rockville, United States
Listing: IPO 2015
Employees: 48
Open positions: None listed
Dealroom signal: 91.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Testing, Biotechnology, Neurology, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Investment activity: 2 companies, latest Mar 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	May 2026	$375M	—	Undisclosed	↗
POST IPO EQUITYOther financing	Jun 2025	$75M	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$59K	0%	−$93M	-158118.6%
2025	$59K	-86.6%	−$10M	-16949.2%
2024	$441K	-77.1%	−$10M	-2267.6%
2023	$1.9M	-89.3%	−$10M	-519.8%
2022	$18M	+260%	−$10M	-55.6%
2021	$5M	-28.6%	−$10M	-200%
2020	$7M	—	−$10M	-142.9%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Avalo Therapeutics website traffic

Latest recorded traffic for Avalo Therapeutics is 2.9K monthly website visits, down 54.7% over the last three months. Avalo Therapeutics's team grew 2.1% over the past year.

Latest monthly visits2.9K 3-month web change-54.7% 1-year team growth+2.1%

Monthly website visitsApr 2016–Oct 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IPImpel PharmaceuticalsDevelops a drug delivery device for central nervous system (CNS) disorders	Seattle, United States	Acquired	45	$108M	—
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational
OLOtolith LabsBuilding hardware products powered by science, data and clinical research for the treatment of vertigo	Washington DC, United States	Operational
SDSuperfluid DiagnosticsMolecular Stethoscope, Inc, a San Diego, CA-based biotechnology company developing novel blood-based early detection	San Diego, United States	Operational
IMImmunArrayA molecular diagnostics company	Rehovot, Israel	Operational
FBFK BiotecnologiaFK Biotecnologia SA manufactures biotech-based products	Porto Alegre, Brazil	Operational
BSBi/ond SolutionsEmpowers biological innovation by engineering hardware solutions for cell-based assays	Delft, Netherlands	Closed